Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Not applicable Interventional Results available

Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

NCT00524472
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Hyperinsulinemic-normoglycemic clamp, insulin at the standard of care levels
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
1,439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 28, 2026, 10:40 AM EDT
Not listed Phase 3 Interventional

Comparative Efficacy, Safety, PK, and Immunogenicity Study

NCT05853354
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab
Biological
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Thousand Oaks, California • Hialeah, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users

NCT02192931
View directory record Official record
Conditions
Depression, Dual Diagnosis, Drug Addiction
Interventions
Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

NCT00409851
View directory record Official record
Conditions
Hypertension
Interventions
valsartan+amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration

NCT01124006
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Intradiscal rhGDF-5, Water for injection
Drug · Other
Lead sponsor
DePuy Spine
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
10
States / cities
Phoenix, Arizona • Santa Monica, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 28, 2026, 10:40 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

NCT05946798
View directory record Official record
Conditions
Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
Interventions
Acetylcholine, Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

WOOP VA: Promoting Weight Management in Primary Care

NCT05014984
View directory record Official record
Conditions
Obesity
Interventions
mental contrasting with implementation intentions, telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!, Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All, Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

NCT00668031
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03439072
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Lilly Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Integrative Approach to Improve Child Outcomes Through Research-based Parent and Teacher Interventions

NCT03431545
View directory record Official record
Conditions
Growth & Development
Interventions
PALS and, BEECH, Control condition
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Months to 35 Months
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

NCT01085734
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Avastin, Osurdex
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)

NCT00018109
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
glutamine, creatine monohydrate
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 10 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00003809
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
73
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Early Phase 1 Interventional Results available

D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder

NCT00842309
View directory record Official record
Conditions
Body Dysmorphic Disorder
Interventions
d-cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Not applicable Interventional

Using Biomarkers to Optimize Antibiotic Strategies in Sepsis

NCT02207114
View directory record Official record
Conditions
Sepsis
Interventions
Biomarker Algorithm Intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Not applicable Interventional Results available

Impact of a Low-Carbohydrate Diet in Pediatric Type 1 Diabetes

NCT03997409
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Dietary Intervention
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 28, 2026, 10:40 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
Apremilast, Etanercept, Placebo tablet, Placebo injection
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 28, 2026, 10:40 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity

NCT01313299
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 28, 2026, 10:40 AM EDT
Completed Not applicable Interventional Results available

Glutamine and Insulin Sensitivity in Type I Diabetes

NCT01467063
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Glutamine, Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 28, 2026, 10:40 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

NCT07094087
View directory record Official record
Conditions
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions
BE1116, FFP
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 10:40 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vasomotor Symptoms and Cardiovascular Control

NCT02202707
View directory record Official record
Conditions
Vasomotor Symptoms, Cardiovascular Health
Interventions
Gabapentin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
45 Years to 58 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 28, 2026, 10:40 AM EDT
Terminated Phase 3 Interventional Results available

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

NCT00360971
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions
palifermin, cisplatin, placebo, neck dissection, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 28, 2026, 10:40 AM EDT